A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19
Liu et al., Infectious Diseases and Therapy, doi:10.1007/s40121-024-00992-5
https://c19early.org/liu20.html